Development of a pan-influenza A neutralizing biological that will be effective against all influenza A strains and can be used every season and during global outbreaks.

Generation of a stable cell line to produce the anti-influenza biologicals compliant with industrial production guidelines.

Creation of a formulation that allows nebulization and hence local delivery of the biological in the airways.

Execution of a cost-effectiveness study of the proposed biological-based solution with a focus on the prophylactic treatment in the elderly.